The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice
Abstract
Current viral vectors for gene therapy are associated with serious safety concerns, including leukemogenesis, and nonviral vectors are limited by low gene transfer efficiency. Here we investigate the therapeutic utility of chemically modified mRNA as an alternative to DNA-based gene therapy. A combination of nucleotide modifications abrogates mRNA interaction with Toll-like receptor (TLR)3, TLR7, TLR8 and retinoid-inducible gene I (RIG-I), resulting in low immunogenicity and higher stability in mice. A single intramuscular injection of modified murine erythropoietin mRNA raises the average hematocrit in mice from 51.5% to 64.2% after 28 days. In a mouse model of a lethal congenital lung disease caused by a lack of surfactant protein B (SP-B), twice weekly local application of an aerosol of modified SP-B mRNA to the lung restored 71% of the wild-type SP-B expression, and treated mice survived until the predetermined end of the study after 28 days.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Substitution of chemically modified nucleotides in messenger ribonucleic acid (mRNA) enhances stability and transfection capability, and decreases immunogenicity1–3”
From Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency (2025) · cites this paper as [2]
In the citing paper
“Conclusive data have also been presented for mRNA as a platform for protein (replacement) therapies (Kormann et al, 2011; Kariko et al, 2012; Zangi et al, 2013; Thess et al, 2015; Balmayor et al, 2016).”
From mRNA mediates passive vaccination against infectious agents, toxins, and tumors (2017) · cites this paper as Kormann et al, 2011
In the citing paper
“Whereas unmodified Epo mRNA was immunostimulatory and failed to induce sufficient protein expression in mice, a few micrograms of nucleoside-modified mRNA were enough to achieve detectable protein expression and physiological effects upon direct administration to murine muscle.”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [26]
In the citing paper
“Our work principally confirms that conventional unmodified mRNAs are inferior to molecules harboring specific nucleoside modifications as suggested by various recent reports,23,24,25,26,27 however, the picture changes dramatically with a sophisticated sequence-engineering.”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [26]
In the citing paper
“Two independent studies on erythropoietin-encoding mRNA found a superiority of nucleoside-modified compared to unmodified mRNA.”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [26]
In the citing paper
“While local administrations may be possible without the need for an mRNA delivery system,26,42”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [26]
In the citing paper
“Kormann et al., demonstrated that 2 weeks following injection of nucleoside-modified mRNA containing 25% thio-uridine and 25% 5-methylcytidine resulted in Epo levels five times greater than that in untreated animals.”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Kormann et al. 2011
In the citing paper
“Unmodified mRNA, on the other hand, showed no significant alterations and merely elicited a considerable immunological response (Kormann et al. 2011).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Kormann et al. 2011
In the citing paper
“In another study by Kormann and colleagues, translation was maximized and innate immune response was reduced in a mouse lung disease model by introducing chemically-modified nucleotides during in vitro transcription of mRNA (IVT-mRNA), coding for surfactant protein B (SP-B) with a 25% replacement of cytidine and uridine by modified 5-methyl cytidine (5-methyl CTP) and 2-thio uridine (2-thio UTP),”
From Human cellular CYBA UTR sequences increase mRNA translation without affecting the half-life of recombinant RNA transcripts (2016) · cites this paper as [19]
In the citing paper
“Therefore, chemists have creatively modified nucleic acid bases, sugar rings, 3 ‘and 5’ ends. These modifications are resistant to nuclease degradation, reduce immunogenicity and improve the interaction with target cells.311”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [311]
In the citing paper
“Studies have shown that when poly(A) tail size increases to 120 bp, the expression level of the corresponding protein increases accordingly. However, when poly(A) tail size is greater than 120 bp, the expression level of the corresponding protein did not increase.152”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [152]
In the citing paper
“Kormann and colleagues152 replaced 25% of mRNA cytosine with m5C and 25% of uridine with s2U, which improved mRNA stability and increased protein translation in mice.”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [152]
In the citing paper
“In contrast, no significant changes were detected with unmodified mRNA, which only evoked a substantial immune activation [44].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [44]
In the citing paper
“In a therapeutic setting, Kormann et al., demonstrated that nucleoside-modified mRNA encoding erythropoietin (Epo), in which 25% thio-uridine and 25% 5-methylcytidine was incorporated, resulted in five times higher Epo levels compared to untreated mice, two weeks after i.m. administration.”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [44]
Citations
Cites
Pfaffl, M. W. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.9.e36 · Cited by 7,377
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Efficacy of Gene Therapy for X-Linked Severe Combined Immunodeficiency
Hacein‐Bey‐Abina, S., Hauer, J., Lim, A., Pïcard, C., Wang, G. P., Berry, C. C., Martinache, C., Rieux‐Laucat, F., Latour, S., Belohradsky, B. H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000164 · Cited by 654
Deficiency of Pulmonary Surfactant Protein B in Congenital Alveolar Proteinosis
Nogee, L. M., deMello, D. E., Dehner, L. P., & Colten, H. R. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302113280606 · Cited by 627
Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Türeci, O., & Sahin, U. (2006) · Blood · doi:10.1182/blood-2006-04-015024 · Cited by 625
Hydrophobic Surfactant Proteins in Lung Function and Disease
Whitsett, J. A., & Weaver, T. E. (2002) · New England Journal of Medicine · doi:10.1056/nejmra022387 · Cited by 519
A randomized controlled study of iron supplementation in patients treated with erythropoietin
Macdougall, I. C., Tucker, B., Thompson, J., Tomson, C., Baker, L. R. I., & Raine, A. E. G. (1996) · Kidney International · doi:10.1038/ki.1996.487 · Cited by 415
Targeted delivery of magnetic aerosol droplets to the lung
Dames, P., Gleich, B., Flemmer, A. W., Hajek, K., Seidl, N., Wiekhorst, F., Eberbeck, D., Bittmann, I., Bergemann, C., Weyh, T., et al. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.217 · Cited by 382
Self-citation
Cited by
Sorted by citations
Items 701–731 of 731
Nanoscience for Nucleotide Delivery in Diabetes
Rastegari, A. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815196535123010008
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4801-1
IVT-mRNA reprogramming of myeloid cells for cancer immunotherapy
Jolly, K. J., & Zhang, F. (2024) · Advances in pharmacology · doi:10.1016/bs.apha.2024.04.004
Introduction to mRNA and mRNA-based therapeutics
Hillery, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28934-7.00001-7
Genome Editing Technologies for Investigation of Activity-Dependent Transcription
Tuscher, J. J., Phillips, R. A., & Day, J. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-68550-7_16
Cancer Vaccines Based on mRNA: Hype or Hope?
de Mey, W., Autaers, D., Bertazzon, G., Esprit, A., Aragon, M. M., Franceschini, L., & Breckpot, K. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch13
Shrilall, C., Arbuthnot, P. B., & Ely, A. (2025) · Microorganisms · doi:10.3390/microorganisms13030604
CELLULAR REPROGRAMMING: AN APPROACH TO TISSUE ENGINEERING AND NANOTECHNOLOGY
dos Santos, A. Í. L., dos Santos, A. M., Gomes, J. A. D. S., da Silva, J. V., dos Santos, L. M. Q. M., Yara, R., & Amorim, R. V. D. S. (2025) · International Journal of Health Science · doi:10.22533/at.ed.15951525180312
Ip-Rp Hplc Method for in Vitro Transcription Process Monitoring and OptimizationPreprint
Shao, N., Huang, T., Li, L., Xu, X., Liang, L., Sun, M., Jin, L., & Zhang, W. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5346623
Advances of Covalent Chemical Modifications of RNA
Li, Y., Cheng, K., Dong, P., Zhou, D., Tian, Y., Zou, J., Fan, J., & Zhao, Y. (2025) · Chemistry - A European Journal · doi:10.1002/chem.202502793
Yu, F., Witman, N., Yan, D., Zhang, S., Zhou, M., Yan, Y., Yao, Q., Ding, F., Yan, B., Wang, H., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13266044
Lu, X., Xu, G., Lin, Z., Zou, F., Liu, S., Zhang, Y., Fu, W., Jiang, J., Ma, X., & Song, J. (2024) · Figshare · doi:10.6084/m9.figshare.26561851
Therapeutic potential of exogenous mRNA encoding recombinant antibodies against viral pathogens
Klotchenko, S. A., & Plotnikova, M. A. (2025) · Medical academic journal · doi:10.17816/maj642736
Ravishankar, S., Bhavya, E., Boopathy, N., Sakthivel, S. R., Sekar, S., Murugathirumal, A., & Nandakumar, K. (2026) · Journal of Bio-X Research · doi:10.34133/jbioxresearch.0076
Stamm, C. E., Zhu, J., Davis-Vargas, C., Dirasantha, O., Thankamani, K., & Rao, V. B. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.28.702426
mRNA Technology Beyond Vaccines: Exploring Potential mRNA-Based Therapies for Autoimmune Diseases
Kharat, M. G., Kulkarni, V. A., Chavan, S. P., Gawali, N. B., & Khandarkar, S. M. (2026) · Asian Journal of Pharmaceutical Research · doi:10.52711/2231-5691.2026.00001
Introduction to RNAi therapeutics
Bunekar, N. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45006-8.00013-6
Shah, K. A., Razzaq, A., Dormocara, A., Elbehairi, S. E. I., Shati, A. A., Alfaifi, M. Y., Iqbal, H., & Cui, J.-H. (2026) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-026-00962-3
The MYB-related transcription factor MYPOP acts as a selective regulator of cancer cell growth
Strunk, J., Hüppner, A., Sial, M., Plath, M., Sheriff, M. B., Wagner, S., Freitag, K., Mikuličić, S., Döring, T., Bopp, T., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-10272-2 · Cited by 1
Manzoor, S., Haseen, S., Javaid, U., & Rizwan, R. (2026) · Immunology Research and Perspectives · doi:10.64229/v8t8pk92
Redox-responsive nanomaterials for mRNA delivery: From rational design to therapeutic applications
Li, M., Wang, Y., Gao, J., An, S., Tang, Z., & Tao, W. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115942
Guo, X., Guo, K., Zhang, C., Su, Y., Zhao, L., Huang, Y., Liang, L., Tan, Y., Song, W., Kong, Y., et al. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.71541
Miles, J. R., Masterson, S., Bellows, E., Fisher, F., Rani, R., Marelli, S., Hardman, C., Grassi, L., Santos, L., James, V. H., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103058
Review Article: mRNA CARs: An Emerging New-Old Idea
Wolf, Y. (2026) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2026066109
Next-generation CAR therapies enabled by mRNA engineering and delivery
Zhao, Q., Wen, Q., Pu, P., Xu, C., Hu, Q., Zhou, Z., Hua, X., & Zhang, X. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.09.001
mRNA Delivery with Lipopolymers to Rejuvenate TRAIL Therapy for Lung Cancer Treatment
Remant, K. C., Nasrullah, M., Sundaram, D. N. M., Patel, D., Sandhu, G., Kucharski, C., & Uludağ, H. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c00483
Bioengineering strategies for improving the immunogenicity of mRNA vaccines
Wang, H., Zhuo, R., Wu, J., & Ouyang, S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02991-z
Li, P., Abdallah, M., Yao, Y., Mugan, R. S., Payne, T. J., Fabb, S. A., Pouton, C. W., & Trevaskis, N. L. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115491
Metadata
- Authors
- Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., Griese, M., Bittmann, I., Handgretinger, R., Hartl, D., Rosenecker, J., & Rudolph, C.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- University Children's Hospital Tübingen (DE)
- Agaplesion Diakonieklinikum Rotenburg (DE)
- Corresponding author
- Kormann, Michael S D
- Rudolph, Carsten
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2011-01-09
- Volume
- 29
- Issue
- 2
- Pages
- 154-157
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2071302752
- Cited by
- 733
- References
- 27
- Citations by year
- 2026: 26 · 2025: 41 · 2024: 59 · 2023: 54 · 2022: 64 · 2021: 61 · 2020: 69 · 2019: 53 · 2018: 56 · 2017: 58 · 2016: 65 · 2015: 48 · 2014: 23 · 2013: 28 · 2012: 17
- FWCI
- 10.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Keywords
- chemically modified mRNA, mRNA therapeutics, erythropoietin, surfactant protein B, immunogenicity, Toll-like receptors, RIG-I, intramuscular injection, hematocrit, non-viral gene therapy, lung disease
- MeSH terms
- Animals, Erythropoietin, Histocytochemistry, Lung, Mice, Transgenic, Proteolipids, RNA, Messenger, Gene Transfer Techniques, RNA Stability, Mice, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
